Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetravalent hyperimmune Pseudomonas globulin G is a specialized intravenous immunoglobulin preparation enriched with antibodies targeting four major immunotypes of *Pseudomonas aeruginosa*. It is used as passive immunotherapy, particularly in patients with severe infections such as sepsis or bacteremia caused by *P. aeruginosa*, especially in high-risk populations like burn patients. The product contains high titers of IgG antibodies specific to the relevant *Pseudomonas* strains responsible for infection, aiming to boost host immunity and improve clinical outcomes. Its mechanism involves direct neutralization of bacterial antigens and enhancement of immune clearance through antibody-mediated processes[1]. This therapy has been associated with increased serum IgG levels and improved survival rates in clinical settings involving severe pseudomonal infections[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tetravalent hyperimmune Pseudomonas globulin G.